Clinical Trial Update: Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men. [Phase 4]

View source ↗

Summary

This Phase 4 clinical trial update reports on the safety, tolerability, and adherence of a fixed-dose combination of tenofovir disoproxil fumarate, emtricitabin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• COMPLERA (Emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate)

Snippet

Sponsor: Andrew Carr | Conditions: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men | Phase 4 | Status: COMPLETED